Log in
Enquire now

Clinical Studies Sponsored by Regeneron Pharmaceuticals

Clinical Studies Sponsored by Regeneron Pharmaceuticals
Clinical Studies Sponsored by AlloVir
Clinical Studies Sponsored by National and Kapodistrian University of Athens
Clinical Studies Sponsored by Baylor College of Medicine
CEOs of data mapping companies
List of companies in Jeff Pulver's investment portfolio
Clinical Studies where
Trial Sponsor
is
Name
Description
NCT Number
Health Conditions in Trial
Clinical Trial Start Date
Study Completion Date
Clinical Trial Study Type
‌
A Trial to Learn if REGV131-LNP1265 is Safe and Works to Help the Body Make Clotting Factor in Pediatric, Adolescent and Adult Patients With Hemophilia B

NCT06379789
July 25, 2024
July 3, 2032
Interventional
‌
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT06669247
December 20, 2024
September 30, 2035
Interventional
‌
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

NCT06292780
April 29, 2024
February 26, 2035
Interventional
‌
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

NCT06541704
October 28, 2024
January 5, 2032
Interventional
‌
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss

NCT06299098
‌
Obesity
March 13, 2024
June 24, 2026
Interventional
‌
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

NCT06608901
December 9, 2024
July 6, 2026
Interventional
‌
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

NCT06469281
Primary peritoneal carcinoma
Primary peritoneal carcinoma
‌
Fallopian tube cancer
June 28, 2024
June 29, 2029
Interventional
‌
Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

NCT06369467
Food allergy
Food allergy
April 12, 2024
April 24, 2026
Interventional
‌
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

NCT06351592
June 28, 2024
April 28, 2029
Interventional
‌
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

NCT06246916
Melanoma
Melanoma
June 7, 2024
April 14, 2033
Interventional
‌
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

NCT06572228
‌
Asthma
September 17, 2024
December 31, 2026
Interventional
‌
Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

NCT06444178
October 4, 2024
July 2, 2025
Interventional
‌
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

NCT06230224
February 5, 2024
July 6, 2027
Interventional
‌
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329
August 15, 2024
May 21, 2030
Interventional
‌
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

NCT04959448
August 12, 2021
August 17, 2026
Observational
‌
Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults

NCT06665828
February 22, 2025
December 12, 2025
Interventional
‌
A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

NCT06602739
Allergic conjunctivitis
Allergic conjunctivitis
October 15, 2024
August 8, 2025
Interventional
‌
A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

NCT06602726
Allergic conjunctivitis
Allergic conjunctivitis
October 15, 2024
August 11, 2025
Interventional
‌
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults

NCT06452771
June 28, 2024
November 2, 2025
Interventional
‌
A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants

NCT06454630
July 10, 2024
March 26, 2025
Interventional
‌
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

NCT06299111
August 31, 2024
June 8, 2026
Interventional
‌
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

NCT06548100
December 30, 2024
July 12, 2027
Interventional
‌
A Trial to Learn How REGN5381 Works and How Safe it is in Adults With Heart Failure With Reduced Ejection Fraction (HFrEF)

NCT06237309
Heart failure
Heart failure
May 2, 2024
July 22, 2026
Interventional
‌
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

NCT06593600
November 13, 2024
April 21, 2026
Interventional
‌
Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers

NCT01197391
‌
Healthy
2010
2012
Interventional
...
Results per page:
249 results
0 selected
249 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us